Cite
HARVARD Citation
Kersting, S. et al. (2022). Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet. 9 (3), pp. e190-e199. [Online].